ATAGI met on Wednesday 25 August 2021 to review the latest developments relating to COVID-19 and COVID-19 vaccine safety. In addition, ATAGI continues to monitor COVID-19 epidemiology in Australia including current COVID-19 outbreaks involving the Delta variant, including in New South Wales, Australian Capital Territory and Victoria.
ATAGI stresses that vaccination is a key public health intervention to prevent infection, transmission and severe disease. ATAGI continues to recommend COVID-19 vaccination for all adults, and specific high-risk adolescents.
ATAGI is encouraged to note that as at 25 August 2021, over 17 million doses of COVID-19 vaccines have been administered in Australia. ATAGI is also encouraged by emerging data from NSW demonstrating that only a small proportion of patients with severe COVID-19 were reported to be vaccinated, consistent with a high vaccine effectiveness against severe disease.
AstraZeneca (Vaxzevria, formerly known as COVID-19 Vaccine AstraZeneca)
Thrombosis and Thrombocytopenia Syndrome (TTS)
ATAGI considered an update from the Therapeutic Goods Administration (TGA) on current confirmed cases of TTS and those under investigation. The latest TGA statement on TTS cases, including clinical outcomes, can be found here.
ATAGI examined estimates of risk of TTS by age group in Australia and note that there have been 116 cases of confirmed or probable TTS (67 confirmed cases; 49 probable cases). To date around 8.8 million doses of AstraZeneca (Vaxzevria) have been administered.
ATAGI notes that International data continues to demonstrate the risk of TTS following a second dose of AstraZeneca (Vaxzevria) is much lower than the risk following a first dose (estimated internationally to be 1.8 per million second doses). ATAGI reinforced the importance of completing a two-dose schedule with the same brand.
Rates of TTS cases are based on first doses of AstraZeneca (Vaxzevria) as of 12 August 2021 (to account for the time to onset of TTS). To that date, approximately 7.9 million doses of AstraZeneca (Vaxzevria) have been administered, made up of around 5.4 million first doses and 2.5 million second doses.
Although estimates of risk based on small numbers of cases are imprecise, the risk of TTS is estimated in Australia at around:
- 2.6 per 100,000 in those
- 1.8 per 100,000 in those ≥60 years.
A breakdown of current rates by decade of age for those aged ≥ 50 years is included here:
| Age bracket (years) | Estimated rate (per 100,000 AZ vaccinations) |
|---|---|
2.5 |
|
50-59 |
2.7 |
60-69 |
1.6 |
70-79 |
2.1 |
≥80 |
1.6 |
ATAGI also noted that the TGA included in their weekly update a detailed breakdown of Australia's confirmed and probable TTS cases using the CDC Criteria.
ATAGI noted these data suggest that the incidence of TTS is higher in younger people and the severity of TTS appears to be higher in younger women. These differences by sex are not seen in older people.
Outcomes have generally been better with early presentation and recognition of the symptoms and appropriate treatment as outlined in the TTS primary care guide. This may contribute to the lower-case fatality ratio observed in Australia compared to those reported internationally. The overall case fatality ratio in Australia (6/115, approximately 5%) is lower than that seen in the United Kingdom (~18%).
ATAGI reinforces that the benefits of vaccination with AstraZeneca (Vaxzevria) strongly outweigh the risks of adverse effects in all Australians ≥60 years. In the context of a COVID-19 outbreak where the supply of Pfizer (Comirnaty) is constrained, ATAGI reinforces adults younger than 60 years old who do not have immediate access to Pfizer (Comirnaty) should re-assess the benefits to them and their contacts from being vaccinated with AstraZeneca (Vaxzevria), versus the rare risk of a serious side effect. In greater Sydney, all individuals aged 18 years and above should strongly consider getting vaccinated with any available vaccine including AstraZeneca (Vaxzevria).
Immune Thrombocytopenia
ATAGI continues to review and closely monitor reports of rare but potentially serious adverse events following immunisation following AstraZeneca (Vaxzevria), including Immune Thrombocytopenia (ITP). It is important for those vaccinated to be aware of some of the symptoms that may be associated with ITP, such easy bruising and bleeding from the nose or gums.
Guillain-Barre Syndrome
ATAGI continues to review and closely monitor reports of rare but potentially serious adverse events following immunisation following AstraZeneca (Vaxzevria), including Guillain-Barre Syndrome (GBS). It is important for those vaccinated to be aware of some of the symptoms that may be associated with GBS, such as muscle weakness, unusual sensation (numbness, pins and needles) and unsteadiness while walking.
At this time, there is no update to the ATAGI statement from 17 June 2021 in relation to the use of AstraZeneca (Vaxzevria), except to note that further clarification has been provided (above) in regards to its use in outbreak settings.
Pfizer (Comirnaty)
ATAGI notes the TGA's recent registration of Pfizer (Comirnaty) for use in children aged 12- 15 years old and has provided a statement on use in this cohort. ATAGI is currently considering advice regarding a broader adolescent program.
Myocarditis and/or Pericarditis
ATAGI continues to review and closely monitor reports of rare but potentially serious adverse events following immunisation following Pfizer (Comirnaty), including myocarditis and/or pericarditis.
ATAGI notes that the TGA is investigated 235 reports of suspected myocarditis and/or pericarditis following Pfizer (Comirnaty). International data demonstrates that the rate of disease is higher in younger individuals, particularly young males and more frequently occurs following the second dose. Most reported cases have been mild, self-limiting and recovered quickly, although further follow-up of these cases is ongoing.
ATAGI has recently published guidance on Myocarditis and Pericarditis after mRNA COVID-19 vaccines. ATAGI reaffirms that the benefits of Pfizer (Comirnaty, currently registered for use in people aged ≥12 years in Australia) outweigh the risks of myocarditis and/or pericarditis for any age groups, and strongly recommend eligible individuals without contraindications to be offered vaccination.
Resources
ATAGI recommends review of the following key resources:
TTS and the use of AstraZeneca (Vaxzevria)
- the ATAGI/THANZ joint statement which provides information about TTS and reaffirms ATAGI's previous advice regarding the safe use of AstraZeneca (Vaxzevria);
- the TTS primary care guide, which provides advice for providers on the consideration and management of suspected TTS cases, noting the importance of early presentation and recognition of TTS;
- the risk-benefit document, which provides advice to help consumers make informed decisions about the risks and benefits of AstraZeneca (Vaxzevria) in different age cohorts and scenarios; and
- additional guidance on the use of COVID-19 vaccines in outbreak settings;
- response to NSW COVID-19 outbreak; and
- additional strategies to combat the risk posed by the Delta variant of concern.
Myocarditis and/or Pericarditis and use of Pfizer (Comirnaty)
- ATAGI and Cardiac Society of Australia and New Zealand guidance on Myocarditis and Pericarditis after mRNA COVID-19 vaccines; and
- ATAGI Statement regarding vaccination of adolescents 12-15 years of age.
